Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 385 to 394 of 394 entries
Sorted by: Best Match Show Resources per page
Psychosocial and Neurobiological Vulnerabilities of the Hospitalized Preterm Infant and Relevant Non-pharmacological Pain Mitigation Strategies.

Frontiers in pediatrics

Shiff I, Bucsea O, Pillai Riddell R.
PMID: 34760849
Front Pediatr. 2021 Oct 25;9:568755. doi: 10.3389/fped.2021.568755. eCollection 2021.

No abstract available.

Cite
Shiff I, Bucsea O, Pillai Riddell R. Psychosocial and Neurobiological Vulnerabilities of the Hospitalized Preterm Infant and Relevant Non-pharmacological Pain Mitigation Strategies. Front Pediatr. 2021;9:568755doi: 10.3389/fped.2021.568755.
Shiff, I., Bucsea, O., & Pillai Riddell, R. (2021). Psychosocial and Neurobiological Vulnerabilities of the Hospitalized Preterm Infant and Relevant Non-pharmacological Pain Mitigation Strategies. Frontiers in pediatrics, 9568755. https://doi.org/10.3389/fped.2021.568755
Shiff, Ilana, et al. "Psychosocial and Neurobiological Vulnerabilities of the Hospitalized Preterm Infant and Relevant Non-pharmacological Pain Mitigation Strategies." Frontiers in pediatrics vol. 9 (2021): 568755. doi: https://doi.org/10.3389/fped.2021.568755
Shiff I, Bucsea O, Pillai Riddell R. Psychosocial and Neurobiological Vulnerabilities of the Hospitalized Preterm Infant and Relevant Non-pharmacological Pain Mitigation Strategies. Front Pediatr. 2021 Oct 25;9:568755. doi: 10.3389/fped.2021.568755. eCollection 2021. PMID: 34760849; PMCID: PMC8573383.
Copy Download .nbib Format: NLM
Is comprehensive geriatric assessment hospital at home a cost-effective alternative to hospital admission for older people?.

Age and ageing

Singh S, Gray A, Shepperd S, Stott DJ, Ellis G, Hemsley A, Khanna P, Ramsay S, Schiff R, Tsiachristas A, Wilkinson A, Young J.
PMID: 34969074
Age Ageing. 2022 Jan 06;51(1). doi: 10.1093/ageing/afab220.

BACKGROUND: hospital level healthcare in the home guided by comprehensive geriatric assessment (CGA) might provide a less costly alternative to hospitalisation for older people.OBJECTIVE: to determine the cost-effectiveness of CGA admission avoidance hospital at home (HAH) compared with hospital...

Cite
Singh S, Gray A, Shepperd S, et al. Is comprehensive geriatric assessment hospital at home a cost-effective alternative to hospital admission for older people?. Age Ageing. 2022;51(1)doi: 10.1093/ageing/afab220.
Singh, S., Gray, A., Shepperd, S., Stott, D. J., Ellis, G., Hemsley, A., Khanna, P., Ramsay, S., Schiff, R., Tsiachristas, A., Wilkinson, A., & Young, J. (2022). Is comprehensive geriatric assessment hospital at home a cost-effective alternative to hospital admission for older people?. Age and ageing, 51(1), . https://doi.org/10.1093/ageing/afab220
Singh, Surya, et al. "Is comprehensive geriatric assessment hospital at home a cost-effective alternative to hospital admission for older people?." Age and ageing vol. 51,1 (2022). doi: https://doi.org/10.1093/ageing/afab220
Singh S, Gray A, Shepperd S, Stott DJ, Ellis G, Hemsley A, Khanna P, Ramsay S, Schiff R, Tsiachristas A, Wilkinson A, Young J. Is comprehensive geriatric assessment hospital at home a cost-effective alternative to hospital admission for older people?. Age Ageing. 2022 Jan 06;51(1). doi: 10.1093/ageing/afab220. PMID: 34969074; PMCID: PMC8753046.
Copy Download .nbib Format: NLM
Israeli Health Care Social Workers' Personal and Professional Concerns during the COVID-19 Pandemic Crisis: The Work-Family Role Conflict.

British journal of social work

Schiff M, Shinan-Altman S, Rosenne H.
PMID: 34393658
Br J Soc Work. 2021 Jul 27;51(5):1858-1878. doi: 10.1093/bjsw/bcab114. eCollection 2021 Jul.

This exploratory study focuses on the personal and professional concerns of Israeli social workers in hospitals and community health settings during the coronavirus (COVID-19) pandemic. Other studies omitted health care social workers' needs and concerns. Participants included 126 social...

Cite
Schiff M, Shinan-Altman S, Rosenne H. Israeli Health Care Social Workers' Personal and Professional Concerns during the COVID-19 Pandemic Crisis: The Work-Family Role Conflict. Br J Soc Work. 2021;51(5):1858-1878doi: 10.1093/bjsw/bcab114.
Schiff, M., Shinan-Altman, S., & Rosenne, H. (2021). Israeli Health Care Social Workers' Personal and Professional Concerns during the COVID-19 Pandemic Crisis: The Work-Family Role Conflict. British journal of social work, 51(5), 1858-1878. https://doi.org/10.1093/bjsw/bcab114
Schiff, Miriam, et al. "Israeli Health Care Social Workers' Personal and Professional Concerns during the COVID-19 Pandemic Crisis: The Work-Family Role Conflict." British journal of social work vol. 51,5 (2021): 1858-1878. doi: https://doi.org/10.1093/bjsw/bcab114
Schiff M, Shinan-Altman S, Rosenne H. Israeli Health Care Social Workers' Personal and Professional Concerns during the COVID-19 Pandemic Crisis: The Work-Family Role Conflict. Br J Soc Work. 2021 Jul 27;51(5):1858-1878. doi: 10.1093/bjsw/bcab114. eCollection 2021 Jul. PMID: 34393658; PMCID: PMC8344873.
Copy Download .nbib Format: NLM
LC-MS/MS Identification of Prolidase Deficiency: A Rare Cause of Infantile Hepatosplenomegaly.

Clinical chemistry

Taibi L, Schlemmer D, Bouchereau J, Causson C, Pichard S, Bourrat E, Melki I, Schiff M, Benoist JF, Imbard A.
PMID: 35015843
Clin Chem. 2022 Jan 07; doi: 10.1093/clinchem/hvab208. Epub 2022 Jan 07.

No abstract available.

Cite
Taibi L, Schlemmer D, Bouchereau J, et al. LC-MS/MS Identification of Prolidase Deficiency: A Rare Cause of Infantile Hepatosplenomegaly. Clin Chem. 2022;doi: 10.1093/clinchem/hvab208.
Taibi, L., Schlemmer, D., Bouchereau, J., Causson, C., Pichard, S., Bourrat, E., Melki, I., Schiff, M., Benoist, J. F., & Imbard, A. (2022). LC-MS/MS Identification of Prolidase Deficiency: A Rare Cause of Infantile Hepatosplenomegaly. Clinical chemistry, . https://doi.org/10.1093/clinchem/hvab208
Taibi, Ludmia, et al. "LC-MS/MS Identification of Prolidase Deficiency: A Rare Cause of Infantile Hepatosplenomegaly." Clinical chemistry vol. (2022). doi: https://doi.org/10.1093/clinchem/hvab208
Taibi L, Schlemmer D, Bouchereau J, Causson C, Pichard S, Bourrat E, Melki I, Schiff M, Benoist JF, Imbard A. LC-MS/MS Identification of Prolidase Deficiency: A Rare Cause of Infantile Hepatosplenomegaly. Clin Chem. 2022 Jan 07; doi: 10.1093/clinchem/hvab208. Epub 2022 Jan 07. PMID: 35015843.
Copy Download .nbib Format: NLM
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Hepatology (Baltimore, Md.)

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N.
PMID: 33811367
Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.

BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In...

Cite
Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021;74(4):1809-1824doi: 10.1002/hep.31843.
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N. (2021). Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology (Baltimore, Md.), 74(4), 1809-1824. https://doi.org/10.1002/hep.31843
Gawrieh, Samer, et al. "Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial." Hepatology (Baltimore, Md.) vol. 74,4 (2021): 1809-1824. doi: https://doi.org/10.1002/hep.31843
Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. PMID: 33811367.
Copy Download .nbib Format: NLM
Medical Supervision of Illinois Public and Private High School Athletics.

The Physician and sportsmedicine

Jones NS, Sethi N, Wieschhaus K, Mak R, Wesolowski M, Schiff A, Tonino PM.
PMID: 33356778
Phys Sportsmed. 2020 Dec 31;1-7. doi: 10.1080/00913847.2020.1868954. Epub 2020 Dec 31.

No abstract available.

Cite
Jones NS, Sethi N, Wieschhaus K, et al. Medical Supervision of Illinois Public and Private High School Athletics. Phys Sportsmed. 2020;1-7doi: 10.1080/00913847.2020.1868954.
Jones, N. S., Sethi, N., Wieschhaus, K., Mak, R., Wesolowski, M., Schiff, A., & Tonino, P. M. (2020). Medical Supervision of Illinois Public and Private High School Athletics. The Physician and sportsmedicine, 1-7. https://doi.org/10.1080/00913847.2020.1868954
Jones, Nathaniel S, et al. "Medical Supervision of Illinois Public and Private High School Athletics." The Physician and sportsmedicine vol. (2020): 1-7. doi: https://doi.org/10.1080/00913847.2020.1868954
Jones NS, Sethi N, Wieschhaus K, Mak R, Wesolowski M, Schiff A, Tonino PM. Medical Supervision of Illinois Public and Private High School Athletics. Phys Sportsmed. 2020 Dec 31;1-7. doi: 10.1080/00913847.2020.1868954. Epub 2020 Dec 31. PMID: 33356778.
Copy Download .nbib Format: NLM
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Hepatology (Baltimore, Md.)

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N.
PMID: 33811367
Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.

BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In...

Cite
Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021;74(4):1809-1824doi: 10.1002/hep.31843.
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N. (2021). Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology (Baltimore, Md.), 74(4), 1809-1824. https://doi.org/10.1002/hep.31843
Gawrieh, Samer, et al. "Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial." Hepatology (Baltimore, Md.) vol. 74,4 (2021): 1809-1824. doi: https://doi.org/10.1002/hep.31843
Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. PMID: 33811367.
Copy Download .nbib Format: NLM
Heterogeneity of PNPT1 neuroimaging: mitochondriopathy, interferonopathy or both?.

Journal of medical genetics

Pennisi A, Rötig A, Roux CJ, Lévy R, Henneke M, Gärtner J, Teke Kisa P, Sarioglu FC, Yiş U, Konczal LL, Burkardt DD, Wu S, Gaignard P, Besmond C, Hubert L, Rio M, Barcia G, Munnich A, Boddaert N, Schiff M.
PMID: 33199448
J Med Genet. 2020 Nov 16; doi: 10.1136/jmedgenet-2020-107367. Epub 2020 Nov 16.

BACKGROUND: Biallelic variants in OBJECTIVE AND METHODS: To document neuroimaging data in six patients with PNPT1 highlighting novel findings.RESULTS: Two patients exhibited striatal lesions compatible with Leigh syndrome; one patient exhibited leukoencephalopathy and one patient had a normal brain...

Cite
Pennisi A, Rötig A, Roux CJ, et al. Heterogeneity of PNPT1 neuroimaging: mitochondriopathy, interferonopathy or both?. J Med Genet. 2020;doi: 10.1136/jmedgenet-2020-107367.
Pennisi, A., Rötig, A., Roux, C. J., Lévy, R., Henneke, M., Gärtner, J., Teke Kisa, P., Sarioglu, F. C., Yiş, U., Konczal, L. L., Burkardt, D. D., Wu, S., Gaignard, P., Besmond, C., Hubert, L., Rio, M., Barcia, G., Munnich, A., Boddaert, N., & Schiff, M. (2020). Heterogeneity of PNPT1 neuroimaging: mitochondriopathy, interferonopathy or both?. Journal of medical genetics, . https://doi.org/10.1136/jmedgenet-2020-107367
Pennisi, Alessandra, et al. "Heterogeneity of PNPT1 neuroimaging: mitochondriopathy, interferonopathy or both?." Journal of medical genetics vol. (2020). doi: https://doi.org/10.1136/jmedgenet-2020-107367
Pennisi A, Rötig A, Roux CJ, Lévy R, Henneke M, Gärtner J, Teke Kisa P, Sarioglu FC, Yiş U, Konczal LL, Burkardt DD, Wu S, Gaignard P, Besmond C, Hubert L, Rio M, Barcia G, Munnich A, Boddaert N, Schiff M. Heterogeneity of PNPT1 neuroimaging: mitochondriopathy, interferonopathy or both?. J Med Genet. 2020 Nov 16; doi: 10.1136/jmedgenet-2020-107367. Epub 2020 Nov 16. PMID: 33199448.
Copy Download .nbib Format: NLM
Mitral Valve Repair vs Replacement in Patients with Previous Mediastinal Irradiation.

Seminars in thoracic and cardiovascular surgery

Pahwa S, Crestanello J, Bernabei A, Schaff H, Dearani J, Lahr B, Greason K.
PMID: 34508812
Semin Thorac Cardiovasc Surg. 2021 Sep 08; doi: 10.1053/j.semtcvs.2021.09.002. Epub 2021 Sep 08.

Long-term outcomes of mitral valve surgery after mediastinal radiation therapy (MRT) are not well characterized. We analyzed long-term survival in patients who underwent mitral valve repair or replacement after MRT. From 2001 to 2018, 148 patients underwent mitral valve...

Cite
Pahwa S, Crestanello J, Bernabei A, et al. Mitral Valve Repair vs Replacement in Patients with Previous Mediastinal Irradiation. Semin Thorac Cardiovasc Surg. 2021;doi: 10.1053/j.semtcvs.2021.09.002.
Pahwa, S., Crestanello, J., Bernabei, A., Schaff, H., Dearani, J., Lahr, B., & Greason, K. (2021). Mitral Valve Repair vs Replacement in Patients with Previous Mediastinal Irradiation. Seminars in thoracic and cardiovascular surgery, . https://doi.org/10.1053/j.semtcvs.2021.09.002
Pahwa, Siddharth, et al. "Mitral Valve Repair vs Replacement in Patients with Previous Mediastinal Irradiation." Seminars in thoracic and cardiovascular surgery vol. (2021). doi: https://doi.org/10.1053/j.semtcvs.2021.09.002
Pahwa S, Crestanello J, Bernabei A, Schaff H, Dearani J, Lahr B, Greason K. Mitral Valve Repair vs Replacement in Patients with Previous Mediastinal Irradiation. Semin Thorac Cardiovasc Surg. 2021 Sep 08; doi: 10.1053/j.semtcvs.2021.09.002. Epub 2021 Sep 08. PMID: 34508812.
Copy Download .nbib Format: NLM
West Syndrome Is an Exceptional Presentation of Pyridoxine- and Pyridoxal Phosphate-Dependent Epilepsy: Data From a French Cohort and Review of the Literature.

Frontiers in pediatrics

Gibaud M, Barth M, Lefranc J, Mention K, Villeneuve N, Schiff M, Maurey H, Barthez MA, Caubel I, Chouchane M, Doummar D, Kossorotoff M, Lamblin MD, Roubertie A, Nabbout R, Van Bogaert P.
PMID: 33748042
Front Pediatr. 2021 Mar 05;9:621200. doi: 10.3389/fped.2021.621200. eCollection 2021.

No abstract available.

Cite
Gibaud M, Barth M, Lefranc J, et al. West Syndrome Is an Exceptional Presentation of Pyridoxine- and Pyridoxal Phosphate-Dependent Epilepsy: Data From a French Cohort and Review of the Literature. Front Pediatr. 2021;9:621200doi: 10.3389/fped.2021.621200.
Gibaud, M., Barth, M., Lefranc, J., Mention, K., Villeneuve, N., Schiff, M., Maurey, H., Barthez, M. A., Caubel, I., Chouchane, M., Doummar, D., Kossorotoff, M., Lamblin, M. D., Roubertie, A., Nabbout, R., & Van Bogaert, P. (2021). West Syndrome Is an Exceptional Presentation of Pyridoxine- and Pyridoxal Phosphate-Dependent Epilepsy: Data From a French Cohort and Review of the Literature. Frontiers in pediatrics, 9621200. https://doi.org/10.3389/fped.2021.621200
Gibaud, Marc, et al. "West Syndrome Is an Exceptional Presentation of Pyridoxine- and Pyridoxal Phosphate-Dependent Epilepsy: Data From a French Cohort and Review of the Literature." Frontiers in pediatrics vol. 9 (2021): 621200. doi: https://doi.org/10.3389/fped.2021.621200
Gibaud M, Barth M, Lefranc J, Mention K, Villeneuve N, Schiff M, Maurey H, Barthez MA, Caubel I, Chouchane M, Doummar D, Kossorotoff M, Lamblin MD, Roubertie A, Nabbout R, Van Bogaert P. West Syndrome Is an Exceptional Presentation of Pyridoxine- and Pyridoxal Phosphate-Dependent Epilepsy: Data From a French Cohort and Review of the Literature. Front Pediatr. 2021 Mar 05;9:621200. doi: 10.3389/fped.2021.621200. eCollection 2021. PMID: 33748042; PMCID: PMC7973036.
Copy Download .nbib Format: NLM
Showing 385 to 394 of 394 entries